Chromogranin A (CgA) - The influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood

Endokrynologia Polska

Volumn 61, Issue 4, 2010, Pages 384-387

  Glinicki, Piotr ^a   Jeske, Wojciech ^a  

^a BIELANSKI HOSPITAL   (Poland)

Author keywords

Chromogranin A; Neuroendocrine tumours

Indexed keywords

CHROMOGRANIN A; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN M; PROTON PUMP INHIBITOR;

ATROPHIC GASTRITIS; BLOOD; CROHN DISEASE; ENTERITIS; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; HYPERCORTISOLISM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; PREGNANCY; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

CHROMOGRANIN A; CHRONIC DISEASE; EATING; FEMALE; GASTRITIS, ATROPHIC; HISTAMINE H2 ANTAGONISTS; HUMANS; HYPERTENSION; INFLAMMATORY BOWEL DISEASES; KIDNEY DISEASES; MALE; PREGNANCY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTON PUMP INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77957260835     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Barakat MT, Meeran K, Bloom S. Neuroendocrine tumours. Endocrine - Related Cancer 2004; 11: 1-18.
2. Payan-Carreira R, Rodrigues P, Carvalho PRF. Chromogranin-A expression in the bovine testis. Anim Repr Sci 2006; 96: 146-153.
3. Yoo AH, You AH, Kang MK et al. Localization of the secretory granule marker protein chromogranin B in the nucleus. J Biol Chem 2002; 277: 16011-16021.
4. Helle KB. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 2004; 79: 769-794.
5. Koshimizu H, Kim T, Cawley NX et al. Chromogranin A: A new proposal for trafficking, processing and induction of granule biogenesis. Regul Pept 2010; 160: 153-159.
6. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin Family. N Engl J Med 2003; 348: 1134-1149.
7. Inomoto C, Osamura RY. Formation of secretory granules by chromogranins. Med Mol Morphol 2009; 42: 201-203.
8. Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 15-31.
9. Kos-Kudła B, Fołtyn W, Zemczak A et al. Diagnostyka i leczenie guzów neuroendokrynnych żoła̧dkowo-jelitowo- trzustkowych (GEP NET). Przeg Gastroenter 2006; 1: 3-9.
10. Nehar D, Lombard-Bohas C, Olivieri S et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol 2004; 60: 644-652. (Pubitemid 38669857)
11. Kos-Kudła B, Bolanowski M, Handkiewicz-Junak D et al. Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recomended by the Polish Network of Neuroendocrine Tumors). Endokrynol Pol 2008; 59: 41-56. (Pubitemid 351547476)
12. Lorenzo MJV. Neuroendocrine tumors - fascination and infrequency. Rev Esp Enferm Dig 2009; 101: 195-208.
13. Nobels FRE, Kwekkeboom DJ, Bouillon R et al. Chromogranin A: its clinical value as marker of neuroendocrine tumors. Eur J Clin Invest 1998; 28: 431-440.
14. Vinik AI, Silva MP, Woltering G et al. Biochemical testing for neuroendocrine tumors. Pancreas 2009; 38: 876-889.
15. Bilek R, Safarik L, Ciprova V et al. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma. Physiol Res 2008; 57: 171-179.
16. Nobels FR, Kwekkeboom DJ, Coopmans et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997; 82: 2622-2628.
17. Granberg D, Stridsberg M, Seensalu R et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999; 84: 2712-2717.
18. Kleveland O, Syversen U, Slørdahl KW et.al. Enterochromaffin-like (ECL) cell hyperplasia/neoplasia as a source of chromogranin A (CgA) increase in blood. Digestation 2001; 64: 71-74.
19. Syversen U, Ramstad H, Gamme K et al. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004; 10: 969-973. (Pubitemid 39388461)
20. Peracchi M, Gebbia C, Basilisco D et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur J Endocrinol 2005; 152: 443-448.
21. Sanduleanu S, Stridsberg M, Jonkers D et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13: 145-153.
22. O'Connor DT, Pandian MR, Carlton E et al. Rapid radioimmunoassay of circulating chromogranin a: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989; 35: 1631-1637.
23. Kadmon D, Thompson TC, Lynch GR et al. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991; 146: 358-361.
24. O'Toole D, Grossman A, Gross D et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology 2009; 90: 194-202.
25. Nobels FRE, Kwekkeboom DJ, Coopmans W et al. A comparison between the diagnostic value of the measurement of gonadotropins, α-subunits and chromogranin A and their response to TRH in clinically non-functioning, α-subunit secreting and gonadotroph pituitary adenoma. J Clin Endocrinol Metab 1993; 77: 784-789.
26. Takiyyuddin MA, Cervenka JH, Hsiao RJ et al. Chromogranin A. Storage and release in hypertension. Hypertension 1990; 15: 237-246.
27. Takiyyuddin MA, Parmer RJ, Kailasam MT et al. Chromogranin A in human hypertension. Hypertension 1995; 26: 213-220.
28. Jansson AM, Røsjø H, Omland T et al. Prognostic value of circulating chromogranin A levels in acute coronary syndromes. Eur Heart J 2009; 30: 25-32.
29. Modlin IM, Gustafsson BI, Moss SF et al. Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 9 (in print)
30. Czerwionka-Szaflarska M, Brazowski J. Inhibitory pompy protonowej w medycynie wieku rozwojowego. Pol Merk Lek 2007; 128: 154-158.
31. Waldum HL, Syversen U. Serum chromogranin A in the control of patients on long-term treatment with inhibitors of acid secretion. Eur J Clin Invest 2001; 31: 741-743. (Pubitemid 34203467)
32. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006; 55: 1217-1221.
33. Giusti M, Sidoti M, Augeri C et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150: 299-303.
34. Waldum HL, Arnestad JS, Brenna E et al. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649-653. (Pubitemid 26426463)
35. Igaz P, Müllner K, Hargitai B et al. Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton-pump inhibitor therapy. Clin Endocrinol 2007; 67: 805-808.
36. Stridsberg M, Eriksson B, Fallström et al. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul Pept 2007; 139: 80-83.
37. Lamberts SW, Hofland LJ, Nobels FRE. Neuroendocrine tumor markers. Front Neuroendocrinol 2001; 22: 309-339.
38. Sørhaug S, Langhammer A, Waldum HL et al. Increased serum levels of Chromogranin A in male smokers with airway obstruction. Eur Respir J 2006; 28: 542-548. (Pubitemid 44794668)
39. Dittadi R, Meo S, Gion M. Biological variation of plasma chromogranin A. Clin Chem Lab Med 2004; 42: 109-110.
40. Drivsholm L, Paloheimo LI, Österlind K. Chromogranin A, a significant prognostic factor in small cell lung cancer. Br J Cancer 1999; 81: 667-671.
41. Tsao KC, Wu JT. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta 2001; 313: 21-29.
42. Takiyyuddin MA, Neumann HP, Cervenka JH et al. Ultradian variations of chromogranin A in human. Am J Physiol 1991; 261: 939-944.
43. Giampaolo B, Angelica M, Antonio S. Chromogranin "A" in normal subjects, essential hypertensives and adrenalectomized patients. Clin Endocrinol 2002;57: 41-50.
44. Elias AN, Wilson AF, Pandian MR et al. Chromogranin A concentrations in plasma of physically active men after acute exercise. Clin Chem 1992; 38: 2348-2349.
45. Glinicki P, Kapuścińska R, Jeske W. Differences in the concentration of chromogranin A (CgA) in the serum and plasma. Endokrynol Pol 2010; 61: 241 (conference abstract).
46. Sanduleanu S, De Bruïne A, Stridsberg M et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid- suppressive therapy. Eur J Clin Invest 2001; 31: 802-811.
47. Frossmark R, Jianu CS, Martinsen TC et al. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scan J Gastroenterol 2008; 43: 20-24.
48. Glinicki P, Jeske W. Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results. Endokrynol Pol 2009; 60: 415-419.